EUCTR2011-006193-36-FR进行中（未招募）1 期
/A - TOBI
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Treatment of diabetic neuropathy with liraglutideEUCTR2013-004375-12-DKCenter of Mech-Sense
进行中（未招募）
不适用
CONTINUING ACCESS TO THE TYROSINE KINASE INHIBITOR OF VEGFR-2,AG-013736 (A406) FOR PATIENTS PREVIOUSLY RECEIVING AG-013736 INCLINICAL TRIALSPatients who have been treated in previous AG-013736 oncology studies.MedDRA version: 14.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-000051-15-ITPFIZER INC.39
进行中（未招募）
1 期
CONTINUING ACCESS TO AG-013736 (A406) FOR PATIENTS PREVIOUSLY RECEIVING AG-013736 IN CLINICAL TRIALSsolid tumorsMedDRA version: 18.0Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 100000004864EUCTR2005-000051-15-HUPfizer Inc., 235 East 42nd Streeet, New York, NY 1001766
招募中
2 期
ONO-4059 therapy for primary intraocular lymphoma :an investigator-initiated clinical trialPrimary intraocular lymphomaPIOLD064090PIOJPRN-jRCT2031200383Taoka Kazuki38
进行中（未招募）
1 期
WITH PONATINIB ON THE TRACK FOR TREATMENT-FREE-REMISSIONIN CHRONIC MYELOID LEUKEMIAEUCTR2018-004564-59-DEHeidelberg University60